This initiative of Eribulin Mesylate Injection will strengthen Glenmark’s U.S. footprint in the oncology and institutional space. With its proven equivalence to Halaven® as well as a sizeable market opportunity, this move demonstrates Glenmark’s ability to deliver value to patients while driving growth in complex generics. https://www.coherentmarketinsights.com/news/glenmark-unveiled-eribulin-mesylate-injection-in-us-market-1445